Attovia Therapeutics, Inc. (ATTO) vs Lexicon Pharmaceuticals, Inc. (LXRX)
A side-by-side comparison of Attovia Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATTO
Attovia Therapeutics, Inc.
$18.06HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
LXRX
Lexicon Pharmaceuticals, Inc.
$1.75HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT
Total return — ATTO vs LXRX
growth of $100 · dividends reinvested · last 1yATTO -17.8% (-17.8%/yr)LXRX -25.6% (-25.6%/yr)ATTO compounded faster over this window
ATTO LXRX
ATTO vs LXRX: by the numbers
- •ATTO is the larger company ($777M vs $775M market cap).
- •Both run net losses; LXRX's is the smaller (-147.38% vs -4490.89% net margin).
Metrics side by side
Valuation
| Metric | ATTO | LXRX |
|---|---|---|
| P/S ratio | N/A | 18.69 |
| P/B ratio | N/A | 4.44 |
Profitability
| Metric | ATTO | LXRX |
|---|---|---|
| Gross margin | 40.44% | 98.85% |
| Operating margin | -4974.74% | -98.21% |
| Net margin | -4490.89% | -147.38% |
| ROE | -40.21% | -35.02% |
| ROIC | -42.83% | -23.16% |
Growth (annualized)
| Metric | ATTO | LXRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 42.36% |
| Total return CAGR (5Y) | N/A | -18.54% |
Go deeper
Dig into the metrics
Attovia Therapeutics ROELexicon Pharmaceuticals ROEAttovia Therapeutics operating marginLexicon Pharmaceuticals operating marginAttovia Therapeutics revenue growthLexicon Pharmaceuticals revenue growthAttovia Therapeutics free cash flowLexicon Pharmaceuticals free cash flow
Attovia Therapeutics & Lexicon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.